SARS-CoV-2-IN-33 is a COVID-19 inhibitor with potent antiproliferative activity against cancer cells; it exhibits strong binding affinity to the SARS-CoV-2 main protease (Mpro) (PDB ID: 6LU7, binding affinity: -8.0 kcal/mol); it can be used in research on cancer and COVID-19.